MacroGenics, Inc. (MGNX) is a Biotechnology company in the Healthcare sector, currently trading at $3.52. It has a SharesGrow Score of 43/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Analyst consensus target is MGNX = $9 (+168.2% upside).
Valuation: MGNX trades at a trailing Price-to-Earnings (P/E) of -2.8 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.92.
Financials: revenue is $150M, +32.6%/yr average growth. Net income is $75M (loss), growing at -186.1%/yr. Net profit margin is -49.9% (negative). Gross margin is 71.1% (-24 pp trend).
Balance sheet: total debt is $107M against $56M equity (Debt-to-Equity (D/E) ratio 1.92, leveraged). Current ratio is 5.1 (strong liquidity). Debt-to-assets is 41.6%. Total assets: $257M.
Analyst outlook: 12 / 22 analysts rate MGNX as buy (55%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 94/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 33/100 (Fail), Moat 43/100 (Fail), Future 64/100 (Pass), Income 10/100 (Fail).
